Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Record expects revenue growth, but visibility limited

(Sharecast News) - Shares in currency and asset manager Record dropped on Friday after the company delivered a set a of weaker financial results for the year to 31 March, and delivered an uncertain outlook. The company said the outlook for the current year is "highly dependent on the closing of large complex deals currently in the pipeline", though revenue is still expected to grow by a low single-digit percentage while earnings per share will be held flat.

Nevertheless, over the medium term, Record still sees the deployment of new funds in private markets driving growth in revenue and EPS.

The comments came as Record reported an 8% fall in revenues to £41.6m for the last fiscal year, driven by lower performance fees, as well as the negative impact of the loss of one large client and another changing strategy.

However, with operating costs falling 6% to £30.8m, the pre-tax profit decline was limited to 2% to £9.1m. Basic earnings per share increased 4% to 5.03p.

"In a year of management and operational transition we have controlled costs while making important investments for the future, particularly in technology and operational infrastructure, while our new office in Paddington is not only a first-class workspace, but also a cost-effective, long-term solution," the company said.

Meanwhile, assets under management fell 1% to $100.9bn, as positive FX movements were outweighed by isolated client losses.

The company announced a final dividend of 2.5p per share, up from 2.45p previously, leading to a full-year payout of 4.65p, up from 4.6p last year.

Shares were down 5.5% at 54.06p by 1033 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.